ProQR Therapeutics (NASDAQ: PRQR)
ProQR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ProQR Therapeutics Company Info
ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa. Its product pipeline includes Sepofarsen, Ultevursen, Axiomer technology, and RNA therapy. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
News & Analysis
Why Shares of ProQR Therapeutics Dropped on Wednesday
The clinical-stage biotech released fourth-quarter and full-year earnings.
Why ProQR Therapeutics Stock Got Slammed Again Monday
Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.
Why ProQR Therapeutics Is Crashing Today
Sepofarsen's failure to meet efficacy endpoints in the Illuminate trial isn't sitting well with investors.
Here's Why ProQR Stock Surged on Thursday
A new collaboration deal with Eli Lilly could be worth up to $1.3 billion.
An End to This Rare Syndrome Could Be an Opportunity for Investors
A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.
Why ProQR Therapeutics Stock Is Popping Today
The company reported positive results from a clinical trial.
Why ProQR Therapeutics N.V. Is Soaring Again Today
Last week's momentum continues for this clinical-stage biotech.
3 Biotech Stocks That Soared This Week: Are They Buys?
Big news lit a fire under these biotech stocks this week. But can their momentum continue?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.